ProMIS Neurosciences (PMN)

Search documents
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
Globenewswire· 2025-03-13 11:00
Core Insights - ProMIS Neurosciences Inc. is set to present preclinical data on computationally-derived vaccines targeting neurodegenerative diseases at the AAN Annual Meeting in April 2025 [1][2] Group 1: Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing antibody therapeutics and vaccines for neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) [9] - The company utilizes a proprietary computational discovery platform, ProMIS™, to identify Disease Specific Epitopes on misfolded proteins [9] - PMN310, the lead product candidate, is a humanized monoclonal antibody designed to selectively bind toxic soluble amyloid-beta oligomers, which are believed to be a primary cause of neurodegeneration in AD [7][8] Group 2: Research and Development - The preclinical studies demonstrated that immunization with a single conformational epitope, peptide 301, resulted in maximal reactivity against AD brain oligomers [4] - The company is exploring a novel approach to vaccine design that targets misfolded toxic proteins, aiming to induce a specific immune response against amyloid-beta oligomers for AD and pathogenic alpha-synuclein for MSA [2][5] - Results indicated that vaccination with conformational B cell epitopes produced high-affinity antibodies with selectivity for pathogenic alpha-synuclein, preserving normal protein function [6] Group 3: Upcoming Presentations - ProMIS Neurosciences will present two key studies at the AAN Annual Meeting: - The first study focuses on optimizing Alzheimer's vaccine configuration to target toxic amyloid-beta oligomers, presented by Dr. Johanne Kaplan on April 9, 2025 [3] - The second study discusses the rational design of a vaccine for synucleinopathies, presented by Dr. Johanne Kaplan on April 8, 2025 [5]
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
Globenewswire· 2025-03-11 11:30
Company Overview - ProMIS Neurosciences, Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) [3] - The company utilizes a proprietary target discovery engine, ProMIS™, which employs a thermodynamic, computational discovery platform to identify Disease Specific Epitopes on misfolded proteins [3] Product Development - The lead product candidate, PMN310, is a humanized monoclonal antibody designed to selectively bind toxic Aβ oligomers, which are implicated in the progression of Alzheimer's disease, while avoiding binding to plaque or monomers [3] - PMN310 has successfully completed a Phase 1a clinical study and is currently in a Phase 1b clinical trial involving Alzheimer's disease patients [3] Upcoming Events - Neil Warma, the CEO of ProMIS Neurosciences, will participate in a fireside chat at the 37th Annual Roth Conference on March 18, 2025, at 8:00 a.m. PT in Dana Point, CA [1] - A live webcast of the event will be available on the company's website for at least 30 days following the event [2]
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease
Globenewswire· 2025-02-25 12:00
Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for Alzheimer’s Disease Six-month Interim Results Expected in 1H 2026 with Topline Results Anticipated in 2H 2026 CAMBRIDGE, Massachusetts, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as A ...
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease
Newsfilter· 2025-02-25 12:00
Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for Alzheimer's Disease Six-month Interim Results Expected in 1H 2026 with Topline Results Anticipated in 2H 2026 CAMBRIDGE, Massachusetts, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as A ...
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
Newsfilter· 2025-01-29 12:30
CAMBRIDGE, Massachusetts, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the Guggenheim ...
ProMIS Neurosciences Issues Letter to Shareholders
Newsfilter· 2025-01-13 15:30
CAMBRIDGE, Massachusetts, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that its Chief Executive Officer, Neil Warma, issued the following letter to the Company's shareholders. Dear ...
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease
Newsfilter· 2025-01-10 12:00
Core Insights - ProMIS Neurosciences Inc. has initiated a Phase 1b clinical trial (PRECISE-AD) for its lead therapeutic candidate PMN310, targeting Alzheimer's disease [1][4] - PMN310 is a humanized IgG1 antibody designed to selectively target toxic oligomers of amyloid-beta, potentially reducing the risk of amyloid-related imaging abnormalities (ARIA) [2][4] - The trial will involve 100 patients with mild cognitive impairment or early Alzheimer's, assessing safety, tolerability, and pharmacokinetics over 12 months [3][4] Company Overview - ProMIS Neurosciences is focused on developing antibody therapeutics for neurodegenerative diseases, utilizing a proprietary platform to identify disease-specific epitopes [7] - PMN310 is designed to bind specifically to toxic amyloid-beta oligomers, which are believed to drive Alzheimer's disease progression [5][7] - The company has completed a Phase 1a study demonstrating a favorable safety profile and is now advancing to Phase 1b [6][7] Clinical Trial Details - The PRECISE-AD trial is a randomized, double-blind, placebo-controlled study evaluating multiple ascending doses of PMN310 [4] - The study will monitor safety, tolerability, pharmacokinetics, and biomarkers, with assessments every three months and frequent MRI scans to check for ARIA [4][3] - Interim data from the trial is expected in the first half of 2026 [4]
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease
Globenewswire· 2025-01-10 12:00
Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patientsCAMBRIDGE, Massachusetts, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b clinical trial (PRECISE-AD) evaluating its lead therapeutic candidate, PMN310, in Alzheimer’s disease (AD). ...
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
GlobeNewswire News Room· 2024-11-14 14:15
Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential target engagement in patients with Alzheimer’s disease On track to initiate Phase 1b clinical trial in patients with Alzheimer’s disease by end of 2024 CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology compa ...
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference
GlobeNewswire News Room· 2024-10-30 12:00
Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement Initiation of Phase 1b clinical trial in Alzheimer's disease patients planned for year-end 2024 CAMBRIDGE, Massachusetts and TORONTO, Ontario, Oct. 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alz ...